BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 28396511)

  • 1. Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker.
    Worst TS; von Hardenberg J; Gross JC; Erben P; Schnölzer M; Hausser I; Bugert P; Michel MS; Boutros M
    Mol Cell Proteomics; 2017 Jun; 16(6):998-1008. PubMed ID: 28396511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer.
    Khan S; Jutzy JM; Valenzuela MM; Turay D; Aspe JR; Ashok A; Mirshahidi S; Mercola D; Lilly MB; Wall NR
    PLoS One; 2012; 7(10):e46737. PubMed ID: 23091600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
    Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
    Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancer.
    Kawakami K; Fujita Y; Matsuda Y; Arai T; Horie K; Kameyama K; Kato T; Masunaga K; Kasuya Y; Tanaka M; Mizutani K; Deguchi T; Ito M
    BMC Cancer; 2017 May; 17(1):316. PubMed ID: 28476099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-Derived Exosomal Long Noncoding RNAs as Promising Diagnostic Biomarkers for Prostate Cancer.
    Wang YH; Ji J; Wang BC; Chen H; Yang ZH; Wang K; Luo CL; Zhang WW; Wang FB; Zhang XL
    Cell Physiol Biochem; 2018; 46(2):532-545. PubMed ID: 29614511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
    McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
    JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer.
    Duijvesz D; Burnum-Johnson KE; Gritsenko MA; Hoogland AM; Vredenbregt-van den Berg MS; Willemsen R; Luider T; Paša-Tolić L; Jenster G
    PLoS One; 2013; 8(12):e82589. PubMed ID: 24391718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
    Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
    Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal proteins as prostate cancer biomarkers in urine: From mass spectrometry discovery to immunoassay-based validation.
    Wang L; Skotland T; Berge V; Sandvig K; Llorente A
    Eur J Pharm Sci; 2017 Feb; 98():80-85. PubMed ID: 27664330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.
    Logozzi M; Angelini DF; Iessi E; Mizzoni D; Di Raimo R; Federici C; Lugini L; Borsellino G; Gentilucci A; Pierella F; Marzio V; Sciarra A; Battistini L; Fais S
    Cancer Lett; 2017 Sep; 403():318-329. PubMed ID: 28694142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis.
    Barceló M; Castells M; Bassas L; Vigués F; Larriba S
    Sci Rep; 2019 Sep; 9(1):13772. PubMed ID: 31551516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma.
    Padda RS; Deng FK; Brett SI; Biggs CN; Durfee PN; Brinker CJ; Williams KC; Leong HS
    Prostate; 2019 May; 79(6):592-603. PubMed ID: 30680751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A claudin 3 and claudin 4-targeted Clostridium perfringens protoxin is selectively cytotoxic to PSA-producing prostate cancer cells.
    Romanov V; Whyard TC; Waltzer WC; Gabig TG
    Cancer Lett; 2014 Sep; 351(2):260-4. PubMed ID: 24952257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease.
    Neuhaus J; Schiffer E; von Wilcke P; Bauer HW; Leung H; Siwy J; Ulrici W; Paasch U; Horn LC; Stolzenburg JU
    PLoS One; 2013; 8(6):e67514. PubMed ID: 23826311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomal Prostate-Specific Membrane Antigen (PSMA) and Caveolin-1 as Potential Biomarkers of Prostate Cancer-Evidence from Serbian Population.
    Matijašević Joković S; Korać A; Kovačević S; Djordjević A; Filipović L; Dobrijević Z; Brkušanin M; Savić-Pavićević D; Vuković I; Popović M; Brajušković G
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics in diagnosis of prostate cancer.
    Davalieva K; Polenakovic M
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
    Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
    Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.